Concord Biotech Ltd share price logo

Concord Biotech Ltd

NSE: CONCORDBIO

BSE: 543960

Small Cap

Pharma Sector

₹1245.60

+15.00

(+1.22%)

as on

bell
The current prices are delayed by 15 mins, login to check live prices.

Tech Chart

What are INDmoney investors doing with Concord Biotech shares?

Based on platform-user behaviour - not analyst opinion or company fundamentals.

Search interest on INDmoney

+14%

Searches for Concord Biotech on INDmoney have increased by 14% over the last 30 days.

Average holding period of indmoney investors

18 days

INDmoney investors hold Concord Biotech shares for an average of 18 days.

Key Events for Concord Biotech

Last Dividend Declared

₹7.55 per share, declared on 29/05/2026

View Dividend History

Concord Biotech Stock Performance

as on October 30, 2026 at 9:31 pm IST

  • Day's Low

    Day's High

    ₹1,215.10
    ₹1,272.40
    downward going graph

    2.45%

    Downside

    2.15%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    ₹987.00
    ₹1,615.00
    downward going graph

    20.76%

    Downside

    29.66%

    Upside

    downward going graph

Concord Biotech share price movements today

Previous Close
₹1,230.60
Open
₹1,224.30
Volume
1.04L
Upper Circuit
₹1,476.70
Lower Circuit
₹984.50
Day's Low - High
₹1,215.10 - ₹1,272.40
52 Week Low - High
₹987.00 - ₹1,615.00

Concord Biotech Historical Returns

1 Month Return
-10.44 %
3 Month Return
-13.39 %
1 Year Return
-14.77 %
3 Year Return
+ 7.13 %
5 Year Return
+ 30.53 %

Concord Biotech Fundamentals

as on October 30, 2026 at 4:01 pm IST

Market Cap

₹13,030.99 Cr

Return on Equity (ROE)

13.74

PE Ratio (TTM)

46.07

Return on capital employed (ROCE)

18.33

Industry PE ratio

51.65

Beta (LTM)

1.06

P/B Ratio

5.26

Dividend Yield

0.74

PEG Ratio

-10.94

Quarterly Earnings Growth YOY

10.32

EPS (TTM)

24.78

Book Value

192.81

Concord Biotech Stock Valuation

as on October 30, 2026 at 4:01 pm IST

Concord Biotech in the last 5 years

  • Overview

  • Trends

Lowest (34.12x)

March 27, 2026

Today (46.07x)

October 29, 2026

Industry (51.65x)

October 29, 2026

Highest (86.91x)

September 20, 2024

LowHigh

Today’s Price to Earnings Ratio: 46.07x

Concord Biotech Technical Analysis

Track how Concord Biotech technical analysis has moved over time to understand its trends.

1 min
5 min
15 min
30 min
1 day
1 week
1 month

Technicals Summary

Bearish

Neutral

Bullish

Neutral

Moving Averages

Bearish

Neutral

Bullish

Bearish

Oscillators

Bearish

Neutral

Bullish

Bullish

Overall

Bearish6
Bullish6
Neutral3

Oscillators

Name

Value

Action

MACD level (12,26)
-0.22
Bullish
CCI (20)
-234.01
Bullish
RSI (14)
51.46
Neutral
Momentum (10)
0.9
Bullish
ADI (14)
17.16
Neutral
Ultimate Oscillator (7,14,28)
51.7
Neutral

Moving Averages

Name

Value

Action

SMA (20)
1245.64
Bullish
EMA (20)
1245.7
Bullish
VWMA (20)
1245.6
Bullish
SMA (50)
1246.25
Bearish
EMA (50)
1246.39
Bearish
SMA (200)
1250.49
Bearish
EMA (200)
1247.46
Bearish
KAMA (200)
1247.83
Bearish
DEMA (200)
1249.45
Bearish

Concord Biotech Ltd vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Concord Biotech with its industry peers.

Company
Analyst View
Market Cap(in ₹ Cr)
5 Year CAGRDebt to Asset Ratio
Net Profit(in ₹ Cr)
Yearly Revenue(in ₹ Cr)
Concord Biotech Ltd image
Concord Biotech Ltd
BUY13,030.996.11%0.502591,054
Kilitch Drugs (India) Ltd image
Kilitch Drugs (India) Ltd
BUY703.856.04%0.6229235
Coral Laboratories Ltd image
Coral Laboratories Ltd
NA172.918.06%0.001685
Vasundhara Rasayans Ltd image
Vasundhara Rasayans Ltd
NA41.35-0.31%0.00535
Godavari Drugs Ltd image
Godavari Drugs Ltd
NA137.0817.94%0.004105
See all

Market expectation of Concord Biotech Stock

Common consensus of the market based on various publicly available news, publications,brokerage expectation and market data

BUY

66.67%

Buy

33.33%

Hold

0.00%

Sell

Concord Biotech Ltd Quarterly Profit & Loss

Figures in Rupees Crores

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Sales
240.8
318.97
215.8
310.18
244.22
429.88
203.99
247.06
277.77
326.08
257.49
309.07
Other Income
11.21
10.81
11.66
10.03
16.56
9.38
15.17
15.64
9.98
15.35
14.1
10.17
Total Income
252
329.78
227.46
320.21
260.78
439.27
219.16
262.7
287.74
341.43
271.59
319.24
Expenses
134.87
186.88
134.52
176.46
146.27
241.01
142.59
158.57
182.76
207.73
175.11
205.35
Operating Profit
105.93
132.09
81.28
133.72
97.95
188.87
61.4
88.49
95.01
118.35
82.38
103.72
Operating Profit Margin %
43.99%
41.41%
37.66%
43.11%
40.11%
43.94%
30.1%
35.82%
34.2%
36.29%
31.99%
33.56%
Profit Before Interest, Tax and Depreciation
117.14
142.9
92.94
143.75
114.51
198.26
76.57
104.13
104.98
133.7
96.48
113.89
Interest
0.5
0.46
0.24
0.1
0.1
0.1
0.06
0.06
0.08
0.08
0.04
0.03
Depreciation
13.54
13.72
13.18
13.31
13.26
14.62
17.78
18.39
18.75
19.54
18.1
18.38
Profit Before Tax
103.1
128.72
79.52
130.34
101.15
183.54
58.73
85.68
86.15
114.08
78.34
95.48
Tax Paid
25.53
33.71
19.92
34.59
25.23
43.16
14.68
22.63
22.52
25.61
20.65
25.91
Profit After Tax
77.57
95.02
59.59
95.74
75.92
140.39
44.06
63.06
63.64
88.47
57.7
69.57
Total Net profit including share of profit / Loss from associate company
77.57
95.02
59.59
95.74
75.92
140.39
44.06
63.06
63.64
88.47
57.7
69.57
EPS
7.41
9.08
5.7
9.15
7.26
13.42
4.21
6.03
6.08
8.46
5.52
6.65
Actual EPS
7.41
9.08
5.7
9.15
7.26
13.42
4.21
6.03
6.08
8.46
5.52
6.65
Adjusted EPS
7.41
9.08
5.7
9.15
7.26
13.42
4.21
6.03
6.08
8.46
5.52
6.65
Diluted EPS
7.41
9.08
5.7
9.15
7.26
13.42
4.21
6.03
6.08
8.46
5.52
6.65

Concord Biotech Ltd Annual Profit & Loss

Figures in Rupees Crores

Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
Sales
616.94
712.93
853.17
1,016.94
1,200.09
1,054.89
Other Income
13.81
23.42
37.27
37.15
44.45
55.26
Total Income
630.75
736.35
890.44
1,054.09
1,244.53
1,110.16
Expenses
289.84
443.3
509.88
585.38
695.08
690.77
Operating Profit
327.1
269.63
343.29
431.56
505.01
364.12
Operating Profit Margin %
53.02%
37.82%
40.24%
42.44%
42.08%
34.52%
Profit Before Interest, Tax and Depreciation
340.91
293.05
380.56
468.71
549.46
419.39
Interest
0.67
5.48
4.51
2.55
0.53
0.28
Depreciation
27.52
50.05
54.03
53.59
54.37
74.46
Profit Before Tax
312.72
237.52
322.02
412.57
494.56
344.65
Tax Paid
77.83
62.58
81.93
104.46
122.91
85.42
Profit After Tax
234.89
174.93
240.09
308.1
371.64
259.23
Total Net profit including share of profit / Loss from associate company
234.89
174.93
240.09
308.1
371.64
259.23
EPS
246.92
183.34
22.95
29.45
35.52
24.78
Actual EPS
246.92
183.34
22.95
29.45
35.52
24.78
Adjusted EPS
22.45
16.67
22.95
29.45
35.52
24.78
Diluted EPS
246.92
183.34
22.95
29.45
35.52
24.78

Concord Biotech Ltd Cash Flow

Figures in Rupees Crores

Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
Net Cash from Operating Activities
155.09
166.81
207.47
246
265.47
244.52
266.88
Cash Flow from Investing Activities
-113.93
-195.45
-111.77
-157.95
-154.61
-159.99
-142.72
Cash Flow from Financing Activities
-42.52
31.36
-100.15
-85.22
-99.22
-98.77
-112.87
Net Cash Flow
-1.35
2.74
-4.48
2.83
11.64
-14.24
11.28

Concord Biotech Stock Shareholding Pattern

Numbers in percentages

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Promoters
44.08%
44.08%
44.08%
44.08%
44.08%
44.08%
44.08%
44.08%
44.08%
44.08%
44.08%
44.09%
DII
8.13%
8.46%
10.4%
9.89%
9.66%
9.16%
8.87%
9.55%
9.58%
9.22%
9.36%
10.95%
FII
0%
6.48%
7.11%
8.1%
8.33%
9.35%
9.11%
8.03%
7.58%
7.8%
7.52%
7.28%
Public
40.46%
40.97%
38.41%
37.93%
37.93%
37.41%
37.95%
38.33%
38.76%
38.9%
39.03%
37.68%
Total Outstanding Shares
10,46,16,204
10,46,16,204
10,46,16,204
10,46,16,204
10,46,16,204
10,46,16,204
10,46,16,204
10,46,16,204
10,46,16,204
10,46,16,204
10,46,16,204
10,46,16,204
Total Shareholders
87,486
83,296
80,737
84,298
82,004
81,219
82,045
82,650
81,815
82,249
83,325
88,365

Mutual Funds Buying / Exiting Concord Biotech

Holdings as of 15 Oct 2026 · based on the latest SEBI-mandated portfolio disclosures

Mutual Funds Buying Concord Biotech

Sorted by largest increase in holding, month-over-month.

Fund Name

Value of Holding

Increase (MoM)

Holding %

Altiva Equity Ex-Top 100 Long-Short Fund Direct Growth

Altiva Equity Ex-Top 100 Long-Short Fund Direct Growth

₹26.25 Cr

₹3.49 Cr (+15.34%)

1.89%

Mutual Funds Exiting Concord Biotech

Sorted by largest decrease in holding, month-over-month.

No exiting activity data available right now

No exiting activity data available right now

Concord Biotech Corporate Actions

View detailed summary of the earnings and dividend history of Concord Biotech.

  • Concord Biotech Ltd Earnings Results

    Concord Biotech Ltd’s net profit jumped 11.12% since last year same period to ₹70.65Cr in the Q2 2026-2027. On a quarterly growth basis, Concord Biotech Ltd has generated 20.71% jump in its net profits since last 3-months.

    Read More

  • Concord Biotech Ltd Dividends May,2026

    In the quarter ending March 2026, Concord Biotech Ltd has declared dividend of ₹7.55 per share on 29 May 2026 - translating a dividend yield of 0.61%.

    Read More about Dividends

Indices Featuring Concord Biotech Stock

Check stock indices that include Concord Biotech.

S&P BSE 250 SmallCap

₹6,557.02

-143.63 (▲2.14%)

Nifty Smallcap 250

₹16,764.55

-336.55 (▲1.97%)

BSE Healthcare

₹50,168.37

+474.08 (▲0.95%)

BSE 500

₹34,248.59

-103.74 (▲0.30%)

Nifty MidSmallcap 400

₹19,500.00

-256.25 (▲1.30%)

S&P BSE 400 MidSmallCap

₹11,628.38

-154.80 (▲1.31%)

Nifty 500

₹21,895.90

-45.60 (▲0.21%)

Insights on Concord Biotech Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 4.40% to 5.84% in Sep 2026 quarter

  • imgPOSITIVE IMPACT

    Promoter Holding Up

    img

    Promoters have increased holdings from 44.08% to 44.09% in Sep 2026 quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 271.59 Cr → 319.24 Cr (in ₹), with an average increase of 14.9% per quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, 58.53 Cr → 70.65 Cr (in ₹), with an average increase of 17.2% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, CONCORDBIO stock has moved down by -6.2%

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 39.03% to 37.68% in Sep 2026 quarter

  • imgNEGATIVE IMPACT

    FII Holding Down

    img

    Foreign Institutions have decreased holdings from 7.52% to 7.28% in Sep 2026 quarter

About Concord Biotech Ltd

Concord Biotech Ltd was originally incorporated as Servomed Pharmaceuticals Private Limited at Ahmedabad Gujarat as a Private Limited Company dated November 23 1984 issued by the Registrar of Companies. Thereafter name of the Company was changed to Concord Biotech Limited dated February 16 2001 which became a Public Company and a fresh Certificate of Incorporation dated November 7 2001 was issued by the RoC.The Company is an Indiabased biopharma and one of the leading global developers and manufacturers of select fermentationbased APIs across immunosuppressants and oncology in terms of market share based on volume in supplying to over 70 countries including regulated markets such as the United States Europe and Japan and India. Presently it is engaged in research and development manufacturing marketing and selling of pharmaceutical products. Its API manufacturing facilities are located at Dholka and Limbasi and formulations facility at Valthera in Gujarat.In 2000 the Company was acquired by the Promoter Mr. Sudhir Vaid. In 2016 the Company launched formulation business in India as well as emerging markets including Nepal Mexico Indonesia Thailand Ecuador Kenya Singapore and Paraguay and have further expanded to the United States. It established a facility at Valthera Gujarat.It set up a joint venture in Japan to grow business in 2018.In 2019 the Company received two ANDA approvals. It expanded their business into critical care segment in India. It commenced marketing of Mycophenolate Mofetil Capsules USP 250 mg. In 2020 Mycophenolate Sodium Tablets got launched in the US market.A second API manufacturing facility at Limbasi was launched which commenced operations in July 2021. As of March 31 2022 the Company had 6 fermentationbased immunosuppressant APIs including tacrolimus mycophenolate mofetil mycophenolate sodium cyclosporine sirolimus and pimecrolimus. It had 3 manufacturing facilities in the state of Gujarat India comprising API manufacturing facilities in Dholka and Limbasi and a formulation manufacturing facility in Valthera which were commercialized in 2000 2021 and 2016 respectively. Their total annual installed fermentation capacity for APIs was 1250 m3 as of March 31 2022. It had a total of 41 manufacturing blocks and 387 reactors in the Dholka and Limbasi facilities. As of March 31 2022 the annual installed production capacity of formulation facility in Valthera amounted to 522.64 million units with an average dosage capability of 0.17 million tablets 0.36 million capsules and 646.46 bottles of dry syrup per shift which is defined as eight hours of production. The Company is planning to raise capital from Public by issuing o 20925652 Equity Shares through Offer for Sale..

Revenue: ₹309.07Cr as on September 2026 (Q2 FY27)
Net Profit: ₹69.57Cr as on September 2026 (Q2 FY27)
Listing date: 18 Aug, 2023
Chairperson Name: SUDHIR JAIRAM VAID
OrganisationConcord Biotech Ltd
HeadquartersAhmedabad
IndustryPharmaceuticals
CEOSUDHIR JAIRAM VAID
E-voting on sharesClick here to vote

FAQs

What is Concord Biotech share price today?

Concord Biotech share price today stands at ₹1245.6 as on at the close of the market. Concord Biotech share today touched a day high of ₹1272.4 and a low of ₹1215.1.

What is the 52 week high and 52 week low range for Concord Biotech share?

Concord Biotech touched a 52 week high of ₹1615 and a 52 week low of ₹987. Concord Biotech share price today i.e. is closed at ₹1245.6, which is -22.87% down from its 52 week high and 26.20% up from its 52 week low.

What is Concord Biotech's market capitalisation today?

Concord Biotech market capitalisation is ₹13,030.99 Cr as on .

How to buy Concord Biotech shares?

To buy Concord Biotech shares, you need to follow these steps:

  • Open a Demat account and Trading account on INDmoney
  • Fund your Trading account
  • Search for CONCORDBIO or Concord Biotech Ltd on the INDmoney app to check live prices of the stock
  • Click on Buy or SIP to place an order to invest in Concord Biotech shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.

What is Concord Biotech trading volume today?

Concord Biotech trading volume is 1.04L as on . This means that 1.04L shares of Concord Biotech were bought and sold on the stock market during today's trading session.